Published On: Wed, Oct 19th, 2016

Immune Design Corp. (IMDZ) Updated Broker Ratings


A number of investment brokers have recently updated their price targets on shares of Immune Design Corp. (IMDZ).

Most recent broker ratings

08/10/2016 – Immune Design Corp. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 17 price target on the stock.

08/18/2015 – Immune Design Corp. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 40 price target on the stock.

05/15/2015 – Cowen began new coverage on Immune Design Corp. giving the company a “outperform” rating.

04/30/2015 – Immune Design Corp. had its “hold” rating reiterated by analysts at Zacks.

08/18/2014 – Wells Fargo began new coverage on Immune Design Corp. giving the company a “outperform” rating.

The share price of Immune Design Corp. (IMDZ) was down -0.69% during the last day of trading, with a day high of 7.40. 29541 shares were traded during the last session.

The stock’s 50 day moving average is 7.39 and its 200 day moving average is 9.68. The stock’s market capitalization is 144.25M. Immune Design Corp. has a 52-week low of 6.02 and a 52-week high of 23.55.

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex-based product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA). GLA Adjuvant Systems (GLAAS) is a discovery platform that works in vivo and is based on a synthetic molecule called glucopyranosyl lipid A (GLA).